Estimating the Economic Value of Emerging Technologies in Chronic Wound Therapy

Overview

Journal Int Wound J

Specialties Emergency Medicine
Orthopedics

Date 2019 Sep 5

PMID 31482663

Citations 1

Authors

Donald E Fetterolf

Affiliations

Soon will be listed here.

Abstract

Estimating the economic value of emerging technologies in clinical medicine presents a number of problems. New technologies may have a limited clinical history, few supportive peer-reviewed publications, and only anecdotal evidence as they enter the market and seek clinician approval and reimbursement from payers. Although clinical efficacy/effectiveness research is a minimal starting point for making the case for adoption of a product, establishing a competitive cost-effectiveness position against other products and establishing the case for economic value must be made as well when presenting to health plans or other payers. Economic valuation methods have been well developed in the business community. Reviewed here are the components of a well-crafted case for the economic value of a product in general and in the wound industry specifically, in a multidomain approach to demonstrate values using demographic, clinical, financial, operational, and intangible assessments.

Citing Articles

Estimating the economic value of emerging technologies in chronic wound therapy.

Fetterolf D Int Wound J. 2019; 16(6):1391-1397.

PMID: 31482663 PMC: 6899938. DOI: 10.1111/iwj.13202.

References

Ashry H, Lavery L, Armstrong D, Lavery D, van Houtum W . Cost of diabetes-related amputations in minorities. J Foot Ankle Surg. 1998; 37(3):186-90. DOI: 10.1016/s1067-2516(98)80108-7. View

Sen C, Gordillo G, Roy S, Kirsner R, Lambert L, Hunt T . Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009; 17(6):763-71. PMC: 2810192. DOI: 10.1111/j.1524-475X.2009.00543.x. View

Koob T, Lim J, Zabek N, Massee M . Cytokines in single layer amnion allografts compared to multilayer amnion/chorion allografts for wound healing. J Biomed Mater Res B Appl Biomater. 2014; 103(5):1133-40. DOI: 10.1002/jbm.b.33265. View

Koob T, Lim J, Massee M, Zabek N, Rennert R, Gurtner G . Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. Vasc Cell. 2014; 6:10. PMC: 4016655. DOI: 10.1186/2045-824X-6-10. View

Marshall D, Burgos-Liz L, IJzerman M, Crown W, Padula W, Wong P . Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. Value Health. 2015; 18(2):147-60. DOI: 10.1016/j.jval.2015.01.006. View

Fetterolf D . Estimating the economic value of emerging technologies in chronic wound therapy. Int Wound J. 2019; 16(6):1391-1397. PMC: 6899938. DOI: 10.1111/iwj.13202. View

Chan B, Cadarette S, Wodchis W, Wong J, Mittmann N, Krahn M . Cost-of-illness studies in chronic ulcers: a systematic review. J Wound Care. 2017; 26(sup4):S4-S14. DOI: 10.12968/jowc.2017.26.Sup4.S4. View

Romanelli M, Gilligan A, Waycaster C, Dini V . Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. Clinicoecon Outcomes Res. 2016; 8:153-61. PMC: 4862353. DOI: 10.2147/CEOR.S104067. View

Fetterolf D, Holt 4th A, Tucker T, Khan N . Estimating clinical and economic impact in case management programs. Popul Health Manag. 2010; 13(2):73-82. DOI: 10.1089/pop.2009.0032. View

10.

Boulton A, Armstrong D, Albert S, Frykberg R, Hellman R, Kirkman M . Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008; 31(8):1679-85. PMC: 2494620. DOI: 10.2337/dc08-9021. View

11.

Barshes N, Saedi S, Wrobel J, Kougias P, Kundakcioglu O, Armstrong D . A model to estimate cost-savings in diabetic foot ulcer prevention efforts. J Diabetes Complications. 2017; 31(4):700-707. DOI: 10.1016/j.jdiacomp.2016.12.017. View

12.

Owens D . Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998; 13(10):716-7. PMC: 1497852. DOI: 10.1046/j.1525-1497.1998.00211.x. View

13.

OBRIEN B, Viramontes J . Willingness to pay: a valid and reliable measure of health state preference?. Med Decis Making. 1994; 14(3):289-97. DOI: 10.1177/0272989X9401400311. View

14.

Sherman R, Anderson S, Dal Pan G, Gray G, Gross T, Hunter N . Real-World Evidence - What Is It and What Can It Tell Us?. N Engl J Med. 2016; 375(23):2293-2297. DOI: 10.1056/NEJMsb1609216. View

15.

Koob T, Lim J, Massee M, Zabek N, Denoziere G . Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater. 2014; 102(6):1353-62. DOI: 10.1002/jbm.b.33141. View

16.

Stevens C, Schriger D, Raffetto B, Davis A, Zingmond D, Roby D . Geographic clustering of diabetic lower-extremity amputations in low-income regions of California. Health Aff (Millwood). 2014; 33(8):1383-90. PMC: 4242846. DOI: 10.1377/hlthaff.2014.0148. View

17.

Fetterolf D . Notes from the field: the economic value chain in disease management organizations. Dis Manag. 2006; 9(6):316-27. DOI: 10.1089/dis.2006.9.316. View

18.

Massee M, Chinn K, Lim J, Godwin L, Young C, Koob T . Type I and II Diabetic Adipose-Derived Stem Cells Respond to Dehydrated Human Amnion/Chorion Membrane Allograft Treatment by Increasing Proliferation, Migration, and Altering Cytokine Secretion. Adv Wound Care (New Rochelle). 2016; 5(2):43-54. PMC: 4742987. DOI: 10.1089/wound.2015.0661. View

19.

Maan Z, Rennert R, Koob T, Januszyk M, Li W, Gurtner G . Cell recruitment by amnion chorion grafts promotes neovascularization. J Surg Res. 2014; 193(2):953-962. PMC: 4425288. DOI: 10.1016/j.jss.2014.08.045. View

20.

Boulton A, Kirsner R, Vileikyte L . Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004; 351(1):48-55. DOI: 10.1056/NEJMcp032966. View